arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Spero Therapeutics, Inc.

SPRO
$1.36 ▲ +0.22 (+19.30%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
12 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Bullish
auto_awesome

Analytical Summary

Spero Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $76.2M
Dividend Yield
Revenue Growth 39.2%
Op. Margin 9.5%
ROIC 10.4%
FCF / Share $-0.23
Trailing P/E 9.1x
Price / Book 1.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

12-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$66.80M
↑ +39.2%
Net Income Profit after all expenses
$8.57M
↑ +112.5%
Operating Margin Operating profit as % of sales
9.5%
↑ +106.2% 55th
FCF / Share Free cash flow per share
$-0.23
↑ +48.1%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
45
Returns
79
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 12 years · 46 quarters